ClinicalTrials.gg
CompletedNCT01466192Updated Jan 6, 2026Results posted

Efficacy and Safety of MP-424, Peginterferon Alfa-2b and Ribavirin in Relapser Genotype 2 Hepatitis C Infected Patients

A Phase 3 interventional study of MP-424 (generic name:Telaprevir) and Ribavirin in Chronic Hepatitis C, sponsored by Tanabe Pharma Corporation. Completed at 1 site in Japan. Open to participants aged 20 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-01-06.

Sponsored by Tanabe Pharma Corporation · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
108
Allocation
Not applicable
Ages
20 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 27 studies testing telaprevir in Hepatitis C, Chronic — none open to participants now, none under way, none of them phase 3. telaprevir · Hepatitis C, Chronic.

Enrollment
9th of 27
108 · median 54
Started
2012
with 8 others
Phase 3
12 of 27
none open now
Registered
13th of 27
by date
Lead sponsor
9 of 27
Tanabe Pharma Corporation

Among the 27 studies testing telaprevir in Hepatitis C, Chronic, this one is the 9th largest by enrollment, is one of 9 that started in 2012, is one of 12 in phase 3, and was the 13th registered.

Hepatitis C, Chronic

950 studies on the registry are indexed under Hepatitis C, Chronic; 8 are open to participants now.

Browse Hepatitis C, Chronic studies →

Open to participants now

None of the 27 studies testing telaprevir in Hepatitis C, Chronic is open now. The open studies under Hepatitis C, Chronic, anywhere →

About telaprevir

telaprevir: first FDA approval 2011 (INCIVEK), first EMA approval 2011. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 5 Hepatitis C, Chronic studies recruiting now, 2 set no upper age limit and 2 stop at 75 or younger; 1 takes children under 18; 1 takes healthy volunteers.

This study: 20 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 27 studies testing telaprevir in Hepatitis C, Chronic as a file.
02

Study summary

This study will evaluate the efficacy and safety of MP-424 with Peginterferon Alfa-2b and Ribavirin (RBV) in patients with genotype 2 hepatitis C, who relapsed after previous treatment.

03

Conditions studied

  • Chronic Hepatitis C

Browse trials for

Keywords

  • Genotype 2
04

Who can participate

Ages eligible
20 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Genotype 2, chronic
  • Relapsers (patient who after previous treatment)
  • Able and willing to follow requirements

Exclusion criteria

Exclusion Criteria:

  • Cirrhosis of the liver or hepatic failure
  • surface antigen-positive or antibodies-positive
  • History of, or concurrent hepatocellular carcinoma
  • History of, or concurrent depression, schizophrenia,; or suicide attempt in the past
  • Pregnant, lactating, or suspected pregnant patients, or male patients whose female partner is pregnant
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
108 participants (actual)

Study arms

  • Experimental
    MP-424

    Drug: MP-424 (generic name:Telaprevir) · Drug: Ribavirin · Drug: Peginterferon alfa-2b

Interventions

06

What researchers measure

Primary outcomes

  1. Undetectable HCV RNA at 24 Weeks After Completion of Drug Administration (SVR, Sustained Viral Response)

    Time frame: After 24 weeks of follow-up

07

Results

Posted Nov 3, 2014

Participant flow

Participant flow — Overall Study
MilestoneMP-424
Started108
Completed104
Not completed4
Withdrew: Physician decision1
Withdrew: Withdrawal by subject3

Outcome measures

PrimaryUndetectable HCV RNA at 24 Weeks After Completion of Drug Administration (SVR, Sustained Viral Response)
Time frame:
After 24 weeks of follow-up
Reported as:
Number · percentage of subjects achieving SVR
Undetectable HCV RNA at 24 Weeks After Completion of Drug Administration (SVR, Sustained Viral Response)
percentage of subjects achieving SVRMP-424
Undetectable HCV RNA at 24 Weeks After Completion of Drug Administration (SVR, Sustained Viral Response)88.0 (80.3 to 93.4)

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
MP-424—12/108 (11.1%)108/108 (100%)
Most frequent serious events
Most frequent serious events
EventMP-424
Decreased appetiteMetabolism and nutrition disorders2/108
Renal impairmentRenal and urinary disorders2/108
Bladder cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/108
Hepatocellular carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/108
Gastrointestinal disorderGastrointestinal disorders1/108
Large intestine polypGastrointestinal disorders1/108
Hepatic function abnormalHepatobiliary disorders1/108
Erythema multiformeSkin and subcutaneous tissue disorders1/108
RhabdomyolysisMusculoskeletal and connective tissue disorders1/108
MalaiseGeneral disorders1/108
Most frequent other events
Showing 10 of 44
Most frequent other events
EventMP-424
AnaemiaBlood and lymphatic system disorders86/108
PyrexiaGeneral disorders86/108
MalaiseGeneral disorders71/108
White blood cell count decreasedInvestigations68/108
Platelet count decreasedInvestigations61/108
Decreased appetiteMetabolism and nutrition disorders54/108
HeadacheNervous system disorders48/108
NauseaGastrointestinal disorders43/108
NasopharyngitisInfections and infestations42/108
RashSkin and subcutaneous tissue disorders42/108

Baseline characteristics

Age, Continuous
Age, Continuous(years)MP-424
Mean56.1 ± 8.0
Sex: Female, Male
Sex: Female, Male(Participants)MP-424
Female55
Male53
08

Study locations

1 site
  • Toranomon Hospital
    Minato-ku, Tokyo, Japan
09

References and documents

Publications

  • Kumada H, Sato K, Takehara T, Nakamuta M, Ishigami M, Chayama K, Toyota J, Suzuki F, Nakayasu Y, Ochi M, Yamada I, Okanoue T. Efficacy of telaprevir-based therapy for difficult-to-treat patients with genotype 2 chronic hepatitis C in Japan. Hepatol Res. 2015 Jul;45(7):745-54. doi: 10.1111/hepr.12416. Epub 2014 Nov 18. PubMed 25196718 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of May 2012, a primary completion of Aug 2013 and a completion of Aug 2013. It does not say whether these dates are actual or estimated.

Results were first posted in Nov 2014, 1 year 3 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 2, 2011
First posted
Nov 7, 2011
Start
May 2012
Primary completionActual
Aug 2013
CompletionActual
Aug 2013
Results first posted
Nov 3, 2014
Last update
Jan 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 6, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01466192
Responsible party
Sponsor
First posted
Nov 7, 2011
Start date
May 2012
Primary completion
Aug 2013
Completion
Aug 2013
Results posted
Nov 3, 2014
Last update
Jan 6, 2026

Study contacts

Kazuoki Kondo, MD
study director · Tanabe Pharma Corporation

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Telaprevir · Ribavirin · Peginterferon alfa-2b

Start the discussion